Table 1.

Galardin treatment of MMTV-PymT transgenic mice

Treatment group
UntreatedPlaceboGalardin
No. mice272626
Age at sacrifice (d)94.1 ± 193.8 ± 194.4 ± 1
Tumor incidence at sacrifice (%)100100100
Final primary tumor volume (geometric mean; cm3)*3.373.291.69
Final primary tumor volume (95% confidence interval of the geometric mean; cm3)2.50-4.562.45-4.411.28-2.23
Dissemination to lymph nodes, brachial + axillary (incidence; %)30 (31/105)29 (30/102)21 (22/103)
Dissemination to brachial lymph nodes (incidence; %)25 (13/52)29 (15/51)22 (11/51)
Dissemination to axillary lymph nodes (incidence; %)34 (18/53)29 (15/51)21 (11/52)
Lung metastasis (incidence; %)100 (27/27)92 (24/26)58 (15/26)
Lung metastasis volume (median; mm3)§1.390.560.0030
Lung metastasis volume (95% confidence interval of the median; mm3)0.23-3.050.19-2.340-0.048
Lung metastasis volume (geometric mean; mm3)0.920.260.0033
  • NOTE: A cohort of FVB-PymT mice were either left untreated or implanted with placebo or Galardin pellets and monitored weekly for tumor onset and killed at age 92 to 96 d. Primary tumor volume and tumor dissemination to regional lymph nodes and to lungs were assessed at the time of sacrifice.

  • * t test on log-transformed data (placebo versus Galardin): P = 0.0014.

  • Not significant.

  • Fisher's exact test (placebo versus Galardin): P = 0.009.

  • § Mann-Whitney U test (placebo versus Galardin): P < 0.0001.

  • The geometric mean is also reported for direct comparison with earlier work (22, 23). To allow logarithmic transformation, metastasis volumes of zero were assigned a value of 10-4 mm3. t test on log-transformed data (placebo versus Galardin): P < 0.0001.